Showing results (691-700 of 829) with videos related to

Sort By:
Pageof 83
Brain Communications|June 15, 2026
Immunosuppression in down syndrome regression disorder: a prospective observational cohort studyJonathan D Santoro, Lilia Kazerooni, Maeve C Lucas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2015
Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer PatientsPeilu Wang, Amir Bahreini, Rekha Gyanchandani, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 8, 2019
Genetic Variant Associated With Survival of Patients With Stage II-III Colon CancerKathryn L Penney, Barbara L Banbury, Stephanie Bien, et al.
Journal of Medicinal Chemistry|August 10, 2019
A Qualified Success: Discovery of a New Series of ATAD2 Bromodomain Inhibitors with a Novel Binding Mode Using High-Throughput Screening and Hit QualificationPaul Bamborough, Chun-Wa Chung, Emmanuel H Demont, et al.
JAMA Oncology|July 1, 2021
Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical TrialOsama E Rahma, Greg Yothers, Theodore S Hong, et al.
Journal of Medicinal Chemistry|June 25, 2024
Design of a Lead-Like Cysteine-Targeting Covalent Library and the Identification of Hits to Cys55 of Bfl-1Simon C C Lucas, Alexander G Milbradt, J Henry Blackwell, et al.
Breast Cancer Research : BCR|December 5, 2019
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancerSamuel A Jacobs, André Robidoux, Jame Abraham, et al.
Breast Cancer Research : BCR|January 24, 2020
Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancerSamuel A Jacobs, André Robidoux, Jame Abraham, et al.
Mayo Clinic Proceedings|February 13, 2026
Utility of Next-Generation Sequencing in Renal Neoplasia, Including Tumors With Clear Cytoplasm and Rare Phenotypes (ELOC/MITF Alterations and Mismatch Repair Deficiency)Michael McCarthy, Antonina A Wojcik, Emily G Barr Fritcher, et al.
JAMA Surgery|May 7, 2025
Breast Tumor-Bed Biopsy for Pathological Complete Response Prediction: The NRG-BR005 Nonrandomized Clinical TrialMark Basik, Reena S Cecchini, Jennifer F De Los Santos, et al.
Pageof 83